1065604-70-7 Usage
Uses
1. Used in Pharmaceutical Industry:
4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]benzoic Acid Ethyl Ester is used as an intermediate in the production of cell death regulators and apoptosis promoters. Its chemical structure allows it to modulate cellular pathways involved in cell survival and death, making it a valuable compound for the development of therapeutic agents targeting various diseases, including cancer.
2. Used in Chemical Research:
In the field of chemical research, 4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]benzoic Acid Ethyl Ester serves as a key intermediate for the synthesis of more complex molecules with potential applications in various industries. Its unique structure and functional groups make it an attractive candidate for further chemical modifications and exploration of its properties.
3. Used in Drug Development:
4-[4-[[2-(4-Chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]benzoic Acid Ethyl Ester is utilized in drug development as a starting material for the creation of novel pharmaceuticals. Its structural features can be exploited to design drugs with specific targeting capabilities, potentially leading to more effective treatments for a range of medical conditions.
Check Digit Verification of cas no
The CAS Registry Mumber 1065604-70-7 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,6,5,6,0 and 4 respectively; the second part has 2 digits, 7 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 1065604-70:
(9*1)+(8*0)+(7*6)+(6*5)+(5*6)+(4*0)+(3*4)+(2*7)+(1*0)=137
137 % 10 = 7
So 1065604-70-7 is a valid CAS Registry Number.
1065604-70-7Relevant academic research and scientific papers
INHIBITING B-CELL LYMPHOMA 2 (BCL-2) AND RELATED PROTEINS
-
Paragraph 00149, (2017/09/05)
Novel compounds inhibiting anti-apoptosis proteins B-cell lymphoma 2 (Bcl-2) and Bcl-XL include compounds of formula (I) and formula (II) disclosed herein, as well as liposome compositions comprising Bcl-2 inhibitor compounds. These compositions are usefu
ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS
-
, (2017/07/14)
Compounds represented by Formula (I) and (II) and salts thereof are described herein. The compounds or salts of Formula (I) and (II) may be used to treat senescence-associated diseases and disorders.
Processes To Make Apoptosis Promoters
-
Page/Page column 32, (2009/12/28)
Processes to make compounds, including N-acylsulfonamide apoptosis promoters are disclosed.
Discovery of an orally bioavailable small molecule inhibitor of prosurvival B-cell lymphoma 2 proteins
Park, Cheol-Min,Bruncko, Milan,Adickes, Jessica,Bauch, Joy,Ding, Hong,Kunzer, Aaron,Marsh, Kennan C.,Nimmer, Paul,Shoemaker, Alexander R.,Song, Xiaohong,Tahir, Stephen K.,Tse, Christin,Wang, Xilu,Wendt, Michael D.,Yang, Xiufen,Zhang, Haichao,Fesik, Stephen W.,Rosenberg, Saul H.,Elmore, Steven W.
experimental part, p. 6902 - 6915 (2009/11/30)
Overexpression of prosurvival proteins such as Bcl-2 and Bcl-XL has been correlated with tumorigenesis and resistance to chemotherapy, and thus, the development of antagonists of these proteins may provide a novel means for the treatment of can
